国内外川崎病临床治疗进展
Progress in Clinical Treatment of Kawasaki Disease at Home and Abroad
DOI: 10.12677/ACM.2019.98137, PDF,   
作者: 吕菊红, 马红茹:陕西省宝鸡市中心医院儿科,陕西 宝鸡;邓 峰:陕西省宝鸡市疾病预防控制中心,陕西 宝鸡
关键词: 川崎病临床治疗国际Kawasaki Disease Clinical Treatment International
摘要: 疾病的临床治疗方法是否科学、有效,根本上有赖于对疾病的发病机制或病因的研究清晰程度。尽管自从全球首个川崎病研究报道至今已过去了半个多世纪,但其发病机制或病因至今尚未研究清楚。虽然目前国内外川崎病的临床治疗仍以药物对症处理为主,但国外临床治疗与研究进展相对较快。在我国川崎病发病呈逐年上升的背景下,有必要及时对国内外川崎病临床治疗与研究进展进行综述,以便为提高我国川崎病临床治疗水平提供参考。
Abstract: Whether the clinical treatment of diseases is scientific and effective depends on the clarity of the pathogenesis or etiology of the disease. Although more than half a century has passed since the world’s first Kawasaki disease research report, its etiology has not yet been studied. Although the clinical treatment of Kawasaki disease at home and abroad is still based on drug symptomatic treatment, the progress of clinical treatment and research abroad is relatively fast. Under the in-creasing trend of Kawasaki disease in China, it is necessary to review the progress of clinical treatment and research of Kawasaki disease at home and abroad in order to provide a reference for improving the clinical treatment level of Kawasaki disease in China.
文章引用:吕菊红, 马红茹, 邓峰. 国内外川崎病临床治疗进展[J]. 临床医学进展, 2019, 9(8): 889-897. https://doi.org/10.12677/ACM.2019.98137

参考文献

[1] Kawasaki, T. (2006) Kawasaki Disease. Proceedings of the Japan Academy, Ser. B, Physical and Biological Science, 82, 59-71. [Google Scholar] [CrossRef] [PubMed]
[2] McCrindle, B.W., Rowley, A.H., Newburger, J.W., et al. (2017) Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals from the American Heart Association. Circulation, 135, e927-e999. [Google Scholar] [CrossRef
[3] 杜忠东, 陈笑征. 川崎病流行病学研究进展[J]. 中国实用儿科杂志, 2017, 32(8): 565-569.
[4] 张新艳, 杨婷婷, 何婷, 等. 2012至2016年单中心川崎病流行病学及临床特征研究[J]. 中国循证儿科杂志, 2018, 13(6): 427-432.
[5] Pilania, R.K., Bhattarai, D. and Singh, S. (2018) Controversies in Diagnosis and Management of Kawasaki Disease. World Journal of Clinical Pediatrics, 7, 27-35. [Google Scholar] [CrossRef] [PubMed]
[6] Lo, M.S. and Newburger, J.W. (2018) Role of Intravenous Immuno-globulin in the Treatment of Kawasaki Disease. International Journal of Rheumatic Diseases, 21, 64-69. [Google Scholar] [CrossRef
[7] Kuo, H.-C., Hsu, Y.-W., Wc, M.-S., et al. (2016) Intravenous Immunoglobulin, Pharmacogenomics, and Kawasaki Disease. Journal of Microbiology, Immunology and Infection, 49, 1-7. [Google Scholar] [CrossRef] [PubMed]
[8] Kuo, H.C., Yang, K.D., Chang, W.C., et al. (2012) Kawasaki Disease: An Update on Diagnosis and Treatment. Pediatrics & Neonatology, 53, 4-11. [Google Scholar] [CrossRef] [PubMed]
[9] Muta, H., Ishii, M., Yashiro, M., et al. (2012) Late Intravenous Immunoglobulin Treatment in Patients with Kawasaki Disease. Pediatrics, 129, e291-297. [Google Scholar] [CrossRef] [PubMed]
[10] Muta, H., Ishii, M., Egami, K., et al. (2004) Early Intravenous Gammaglobulin Treatment for Kawasaki Disease: The Nationwide Surveys in Japan. The Journal of Pediatrics, 144, 496-499. [Google Scholar] [CrossRef] [PubMed]
[11] Rowley, A.H. (2015) The Complexities of the Diagnosis and Management of Kawasaki Disease. Infectious Disease Clinics of North America, 29, 525-537. [Google Scholar] [CrossRef] [PubMed]
[12] Fujimaru, T., Ito, S., Masuda, H., et al. (2014) Decreased Levels of Inflammatory Cytokines in Immunoglobulin-Resistant Kawasaki Disease after Plasma Exchange. Cytokine, 70, 156-160. [Google Scholar] [CrossRef] [PubMed]
[13] Bayers, S., Shulman, S.T. and Paller, A.S. (2013) Kawasaki Dis-ease: Part II. Complications and Treatment. Journal of the American Academy of Dermatology, 69, 513e1-8. [Google Scholar] [CrossRef] [PubMed]
[14] Rahbarimanesh, A., Taghavi-Goodarzi, M., Mohammadinejad, P., et al. (2014) Comparison of High-Dose versus Low-Dose Aspirin in the Management of Kawasaki Disease. Indian Journal of Pediatrics, 81, 1403. [Google Scholar] [CrossRef] [PubMed]
[15] Dallaire, F., Fortier-Morissette, Z., Blais, S., et al. (2017) Aspirin Dose and Prevention of Coronary Abnormalities in Kawasaki Disease. Pediatrics, 139, e20170098. [Google Scholar] [CrossRef] [PubMed]
[16] Ho, L.G.Y. and Curtis, N. (2017) What Dose of Aspirin Should Be Used in the Initial Treatment of Kawasaki Disease. Archives of Disease in Childhood, 102, 1180-1182. [Google Scholar] [CrossRef] [PubMed]
[17] Zhu, F.H. and Ang, J.Y. (2016) The Clinical Diagnosis and Management of Kawasaki Disease: A Review and Update. Current Infectious Disease Reports, 18, 32. [Google Scholar] [CrossRef] [PubMed]
[18] Kato, H., Koike, S. and Yokoyama, T. (1979) Kawasaki Disease: Effect of Treatment on Coronary Artery Involvement. Pediatrics, 63, 175-179.
[19] Eleftheriou, D., Levin, M., Shin-gadia, D., et al. (2014) Management of Kawasaki Disease. Archives of Disease in Childhood, 99, 74-83. [Google Scholar] [CrossRef] [PubMed]
[20] Kobayashi, T., Saji, T., Otani, T., et al. (2012) Efficacy of Immunoglobulin plus Prednisolone for Prevention of Coronary Artery Abnormalities in Severe Kawasaki Disease: Raise Study, a Randomised, Open-Label, Blinded-Endpoints Trial. The Lancet, 379, 1613-1620. [Google Scholar] [CrossRef
[21] Singh, S., Sharma, A. and Jiao, F. (2016) Kawasaki Disease: Issues in Diagnosis and Treatment—A Developing Country Perspective. Indian Journal of Pediatrics, 83, 140-145. [Google Scholar] [CrossRef] [PubMed]
[22] Singh, S., Newburger, J.W., Kuijpers, T., et al. (2015) Manage-ment of Kawasaki Disease in Resource-Limited Settings. The Pediatric Infectious Disease Journal, 34, 94-96. [Google Scholar] [CrossRef
[23] Adachi, S., Sakaguchi, H., Kuwahara, T., et al. (2010) High Regression Rate of Coronary Anuerysms Developed in Patients with Immune Globulin Resistant Kawasaki Disease Treated with Steroid Pulse Therapy. The Tohoku Journal of Experimental Medicine, 220, 285-290. [Google Scholar] [CrossRef] [PubMed]
[24] Saneeymehri, S., Baker, K. and So, T.Y. (2015) Overview of Pharma-cological Treatment Options for Pediatric Patients with Refractory Kwasaki Disease. The Journal of Pediatric Phar-macology and Therapeutics, 20, 163-177.
[25] Ogata, S., Ogihara, Y., Honda, T., et al. (2012) Corticosteroid Pulse Combination Therapy for Refractory Kawasaki Disease: A Randomized Trial. Pediatrics, 129, e17-e23. [Google Scholar] [CrossRef] [PubMed]
[26] Chen, S., Dong, Y., Yin, Y., et al. (2013) Intravenous Immuno-globulin plus Corticosteroid to Prevent Coronary Artery Abnormalities in Kawasaki Disease: A Meta-Analysis. Heart, 99, 76-82. [Google Scholar] [CrossRef] [PubMed]
[27] Weng, K.P., Ou, S.F., Lin, C.C., et al. (2011) Recent Advances in the Treatment of Kawasaki Disease. Journal of the Chinese Medical Association, 74, 481-484. [Google Scholar] [CrossRef] [PubMed]
[28] Yu, J.J. (2015) Use of Corticosteroids during Acute Phase of Kawasaki Disease. World Journal of Clinical Pediatrics, 4, 135. [Google Scholar] [CrossRef] [PubMed]
[29] Lim, Y.J. and Jung, J.W. (2014) Clinical Outcomes of Initial Dexamethasone Treatment Combined with a Single High Dose of Intravenous Immunoglobulin for Primary Treatment of Kawasaki Disease. Yonsei Medical Journal, 55, 1260-1266. [Google Scholar] [CrossRef] [PubMed]
[30] Portman, M.A., Olson, A., Soriano, B., et al. (2011) Etanercept as Adjunctive Treatment for Acute Kawasaki Disease: Study Design and Rationale. American Heart Journal, 161, 494-499. [Google Scholar] [CrossRef] [PubMed]
[31] Agarwal, S. and Devendra, K. (2017) Kawasaki Disease: Etiopathogenesis and Novel Treatment Strategies. Expert Review of Clinical Immunology, 13, 247-258. [Google Scholar] [CrossRef
[32] Mori, M., Imagawa, T., Hara, R., et al. (2012) Efficacy and Limitation of Infliximab Treatment for Children with Kawasaki Disease Intractable to Intravenous Immunoglobulin Therapy: Report of an Open-Label Case Series. The Journal of Rheumatology, 39, 864-867. [Google Scholar] [CrossRef] [PubMed]
[33] Tremoulet, A.H., Jain, S., Jaggi, P., et al. (2014) Infliximab for In-tensification of Primary Therapy for Kawasaki Disease: A Phase 3 Randomised, Double-Blind, Placebo-Controlled Trial. The Lancet, 383, 1731-1738. [Google Scholar] [CrossRef
[34] Williams, R.V., Wilke, V.M., Tani, L.Y., et al. (2002) Does Abciximab Enhance Regression of Coronary Aneurysms Resulting from Kawasaki Disease. Pediatrics, 109, E4. [Google Scholar] [CrossRef] [PubMed]
[35] Choueiter, N.F., Olson, A.K., Shen, D.D., et al. (2010) A Prospective Open Label Trial of Etanercept as Adjunctive Therapy for Kawasaki Disease. The Journal of Pediatrics, 157, 960-966. [Google Scholar] [CrossRef] [PubMed]
[36] Mori, M., Imagawa, T., Katakura, S., et al. (2004) Efficacy of Plasma Exchange Therapy for Kawasaki Disease Intractable to Intravenous Gamma-Globulin. Modern Rheumatology, 14, 43-47. [Google Scholar] [CrossRef] [PubMed]
[37] Matsui, M., Okuma, Y., Yamanaka, J., et al. (2015) Kawasaki Disease Refractory to Standard Treatments That Responds to a Combination of Pulsed Methylprednisolone and Plasma Exchange: Cytokine Profiling and Literature Review. Cytokine, 74, 339-342. [Google Scholar] [CrossRef] [PubMed]
[38] Sonoda, K., Mori, M., Hokosaki, T., et al. (2014) Infliximab plus Plasma Exchange Rescue Therapy in Kawasaki Disease. The Journal of Pediatrics, 164, 1128-1132. [Google Scholar] [CrossRef] [PubMed]
[39] Tremoulet, A.H., Pancoast, P., Franco, A., et al. (2012) Cal-cineurin Inhibitor Treatment of Intravenous Immunoglubulin Resistant Kawasaki Disease. The Journal of Pediatrics, 161, 506-512. [Google Scholar] [CrossRef] [PubMed]
[40] Kuijpers, T.W., Biezeveld, M., Achterhuis, A., et al. (2003) Longstanding Obliterative Panarteritis in Kawasaki Disease: Lack of Cyclosporin A Effect. Pediatrics, 112, 986-992. [Google Scholar] [CrossRef] [PubMed]
[41] Suzuki, H., Terai, M., Hamada, H., et al. (2011) Cyclosporin A Treatment for Kawasaki Disease Refractory to Initial and Additional Intravenous Immunoglobulin. The Pediatric Infectious Disease Journal, 30, 871-876. [Google Scholar] [CrossRef
[42] Aoyagi, R., Hamada, H., Sato, Y., et al. (2015) Study Pro-tocol for a Phase III Multicentre, Randomised, Open-Label, Blinded-End Point Trial to Evaluate the Efficacy and Safety of Immunoglobulin plus Cyclosporin A in Patients with Severe Kawasaki Disease (KAICA Trial). BMJ Open, 5, e009562. [Google Scholar] [CrossRef] [PubMed]
[43] Rodrigues-Diez, R., González-Guerrero, C., Ocaña-Salceda, C., et al. (2016) Calcineurin Inhibitors Cyclosporine A and Tacrolimus Induce Vascular Inflammation and Endothelial Activation through TLR4 Signaling. Scientific Reports, 6, Article No. 27915. [Google Scholar] [CrossRef] [PubMed]
[44] Al-Homsi, A.S., Roy, T.S., Cole, K., et al. (2015) Post-Transplant High-Dose Cyclophosphamide for the Prevention of Graft-versus-Host Disease. Biology of Blood and Marrow Trans-plantation, 21, 604-611. [Google Scholar] [CrossRef] [PubMed]
[45] Falcini, F. (2006) Kawasaki Disease. Current Opinion in Rheu-matology, 18, 33-38. [Google Scholar] [CrossRef] [PubMed]
[46] Wong, P.T. and Choi, S.K. (2015) Mechanisms and Implications of Dual-Acting Methotrexate in Folate-Targeted Nanotherapeutic Delivery. International Journal of Mo-lecular Sciences, 16, 1772-1790. [Google Scholar] [CrossRef] [PubMed]
[47] Shulman, S.T. (1988) Management of Kawasaki Disease. The Journal of Pediatrics, 113, 1116-1117. [Google Scholar] [CrossRef
[48] Lee, M.S., An, S.Y., Jang, G.C., et al. (2002) A Case of In-travenous Immunoglobulin Resistant Kawasaki Disease Treated with Methotrexate. Yonsei Medical Journal, 43, 527-532. [Google Scholar] [CrossRef] [PubMed]
[49] Lee, T.J., Kim, K.H., Chun, J.K., et al. (2008) Low-Dose Methotrexate Therapy for Intravenous Immunoglobulin-Resistant Kawasaki Disease. Yonsei Medical Journal, 49, 714-718. [Google Scholar] [CrossRef] [PubMed]
[50] Kim, N.Y., Choi, D.Y., Jung, M.J., et al. (2008) A Case of Refractory Kawasaki Disease Complicated by Peripheral Ischemia. Pediatric Cardiology, 29, 1110-1114. [Google Scholar] [CrossRef] [PubMed]
[51] Magalhães, C.M.R., Alves, N.R., Melo, A.V., et al. (2012) Cata-strophic Kawasaki Disease Unresponsive to IVIG in a 3-Month-Old Infant: A Diagnostic and Therapeutic Challenge. Pediatric Rheumatology Online Journal, 10, 28. [Google Scholar] [CrossRef] [PubMed]
[52] 《中华儿科杂志》编辑委员会, 中华医学会儿科学分会心血管学组, 中华医学会儿科学分会免疫学组. 川崎病专题讨论会纪要[J]. 中华儿科学杂志, 2007, 45(11): 826-830.
[53] 梁亚晓, 梁艳萍. 不同剂量丙种球蛋白联合阿司匹林治疗川崎病的临床研究[J]. 泰山医学院学报, 2019, 40(1): 72-74.
[54] 张艳红. 不同剂量的丙种免疫球蛋白治疗方案对川崎病患儿冠状动脉病变的影响观察[J]. 现代诊断与治疗, 2018, 29(1): 95-96.
[55] 江佳峪, 赵世权, 高小平. 不同途径给予激素治疗丙种球蛋白无反应型川崎病临床观察[J]. 解放军医药杂志, 2019, 31(1): 63-66.
[56] 刘卓勋, 温晓莹, 郑燕霞, 等. 川崎病接受首次静脉使用免疫球蛋白标准剂量后病情反应情况与治疗前实验室指标相关性的Meta分析[J]. 中国循证医学杂志, 2018, 18(4): 347-353.
[57] 何炜星, 张涤. 张涤教授治疗川崎病经验拾萃[J]. 湖南中医药大学学报, 2019, 39(2): 218-221.
[58] 安娜, 李晨, 段保湘, 等. 中西医结合治疗川崎病疗效评价[J]. 中华中医药学刊, 2017, 35(5): 1310-1312.
[59] 李小青, 匡琳, 吴俊, 等. 川崎病治疗进展[J]. 现代临床医学, 2016, 42(5): 328-330.
[60] 郭俊, 沈下贤, 张必利, 等. 介入治疗川崎病并发冠状动脉损害1例并文献回顾[J]. 第二军医大学学报, 2015, 36(11): 1275-1277.
[61] 张鹏宇, 汤楚中, 潘绪, 等. 英夫利西单抗与 IVIG 治疗 IVIG 初治无效川崎病效果比较[J]. 中国医学前沿杂志(电子版), 2018, 10(5): 60-63.
[62] 吴洁. 丙种球蛋白无反应型川崎病预测评分系统的验证及血浆置换治疗川崎病269例的系统评价[D]: [硕士学位论文]. 苏州: 苏州大学, 2018.